Table 3.

Base-case results

Screening strategy	Cost, $	Effectiveness, QALYs	Marginal cost, $	Marginal effectiveness QALYs	Marginal cost-effectiveness ratio, $/QALY
Primary Model: Discounted (3% per year)
No screen	2,200.96	29.33559	-	-	-
Questionnaire/TST if +	2,218.20	29.33555	17.24	−0.00004	dominated
Universal TST	2,480.97	29.33471	280.01	−0.00088	dominated
Primary Model: Non-discounted
No screen	2,216.16	71.75844	-	-
Questionnaire/TST if +	2,228.69	71.75839	12.53	−0.00005	dominated
Universal TST	2,485.93	71.75731	269.76	−0.00113	dominated
Secondary Model: Discounted (3% per year)
No screen	2,200.96	29.33559
Questionnaire/IGRA if +	2,208.01	29.33560	7.05	0.00001	705,000
Questionnaire/TST if +	2,218.20	29.33555	10.02	−0.00005	dominated
TST/IGRA if +	2,272.43	29.33558	64.42	−0.00002	dominated
Universal IGRA	2,304.89	29.33553	96.88	−0.00007	dominated
Universal TST	2,480.97	29.33471	272.97	−0.00089	dominated
Secondary Model: Non-discounted
No screen	2,216.16	71.75844	-	-	-
Questionnaire/IGRA if +	2,218.68	71.75845	2.52	0.00001	252,000
Questionnaire/TST if +	2,228.69	71.75839	10.01	−0.00006	dominated
TST/IGRA if +	2,278.77	71.75844	60.09	−0.00001	dominated
Universal IGRA	2,310.25	71.75836	91.57	−0.00009	dominated
Universal TST	2,485.93	71.75731	267.24	−0.00114	dominated

^*Dominated indicates the strategy is both more costly and less/equally effective compared to the next best strategy

Abbreviation: QALY, quality-adjusted life-year; ; IGRA, interferon-γ release assay; TST, tuberculin skin testing